(IN BRIEF) GSK, a leading pharmaceutical company, has unveiled plans to conduct Phase III trials in 2024 for a low…
Tony Wood übernimmt im August 2022 die volle Verantwortung für die F&E von GSK Hal Barron wechselt im August 2022…
Tony Wood to assume full accountability for GSK R&D in August 2022 Hal Barron to transition in August 2022 from…
Brentford, United Kingdom, 14-Aug-2018 — /EuropaWire/ — GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Iain Mackay has been appointed GSK’s next…